EGFR and non-small cell lung carcinoma: Subsequently, a survival analysis demonstrated that mutant-EGFR NSCLC patients harboring EGFR signaling pathway alterations had poorer PFS than those without EGFR signaling pathway alterations (7.6 months vs. 16.3 months, HR = 2.07, 95% CI = 1.35–3.18, Fig. 1c), but not for OS analysis (21.8 months vs. 33.5 months, HR = 1.57,95% CI = 0.94–2.63, Fig. 1d).